Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Idiopathic Gastroparesis
NCT04300127Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Oct 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pioglitazone in idiopathic gastroparesis (IG), sponsored by Johns Hopkins University. Primary endpoint: Gastroparesis Cardinal Symptom Index at 3 months. Started Oct 2019; status: completed.
02
Drugs
pioglitazone
03
Conditions
idiopathic gastroparesis (IG)
Beyond the preview
Go deeper on NCT04300127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300127.